Review of thalidomide use in the pediatric population
- 1 April 2015
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 72 (4) , 703-711
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous diseaseClinical Immunology, 2013
- Clinical Evidence of Pharmacokinetic Changes in Thalidomide TherapyDrug Metabolism and Pharmacokinetics, 2013
- TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under ThalidomideCurrent Topics in Medicinal Chemistry, 2012
- The rise, fall and subsequent triumph of thalidomide: lessons learned in drug developmentTherapeutic Advances in Hematology, 2011
- Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2011
- Thalidomide Use in the USDrug Safety, 2006
- Thalidomide: dermatological indications, mechanisms of action and side-effectsBritish Journal of Dermatology, 2005
- Phase I and Pharmacokinetic Study of Thalidomide With Carboplatin in Children With CancerJournal of Clinical Oncology, 2004
- Thalomid?? (Thalidomide) CapsulesDrug Safety, 2001
- Thalidomide treatment for chronic graft‐versus‐host diseaseBritish Journal of Haematology, 1991